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Background: HIV and HCV infections are basic issues of many health systems. Since HIV 
and HCV are transmitted similarly, it is common to become infected by them simultane-
ously. No consensus exists on the eﬀect of HCV infection on the survival of HIV-infected 
patients.
Objectives: This study aimed to investigate the issue in a relatively large cohort of pa-
tients who had a high prevalence of this coinfection in Shiraz (South of Iran).
Patients and Methods: In this historical cohort study, we evaluated the survival time of 
1338 HIV-infected individuals who had been referred to a behavioral consultation center 
in Shiraz over 10 years (from April 2001 to July 2011). Kaplan-Meier method and log-rank 
test were used to investigate patient survival and compare their survival curves, respec-
tively. Moreover, Cox proportional hazards model was used to examine the eﬀect of HCV 
infection on patient survival after control for age, sex, having the injection drug use 
(IDU) risk factor, CD4 count at baseline, more than a 30% decline in CD4 cell count, and 
highly active antiretroviral therapy (HAART).
Results: In our cohort, 1044 patients (78.03%) were infected by HCV. The median follow-up 
was 43.48 months (95% CI = 61.18–26.63). The median survival time in HCV-infected and 
uninfected patients was 163.8 and 194.8 months, respectively (P = 0.039). After control-
ling for other covariates, HCV infection increased the mortality rate 2.13 times more in 
HCV-infected patients than HCV -uninfected patients (CI: 95%; 1.1–4.52).
Conclusions: HCV infection increases AIDS-related deaths. To control HCV infection and 
transmission and eliminate HCV, timely diagnosis and treatment and serious harm re-
duction programs must be implemented. 
 Implication for health policy/practice/research/medical education:
There are limited data and study about the impact of HCV on HIV/AIDS related mortality in Iran. Our study enforces on importance 
of HIV/HCV coinfection for policy makers to persuade this issue in our society.
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1. Background
HIV and HCV infections are basic issues that are faced 
by health systems in many societies. Because HIV and 
HCV are transmitted in similar ways, it is common to be-
come coinfected by them (1-3). It is estimated that 34–38.6 
million people around the world are infected by HIV 
compared with 170–200 million by HCV and 4–5 million 
people who are coinfected with HIV and HCV (4, 5). It is 
also estimated that 68,000–110,000 people (6) (average = 
86,000, less than 0.2%) in Iran are infected by HIV (7), and 
less than 1% is infected by HCV (8). The prevalence of HIV 
and HCV coinfection depends on facilitating risk factors, 
such as IDU, and varies between countries—even between 
various areas within a country (9-12). Surveys show that 107
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the prevalence of this coinfection in HIV-infected indi-
viduals who have a background of IDU is 92%, 91%, and 
over 90% in the US (13), Russia (14), and Asia (12), respec-
tively. Although many studies have shown that HIV infec-
tion leads to a decrease in HCV clearance and increases in 
viral load and complications from the infection (15-17), no 
consensus exists regarding the eﬀect of HCV infection on 
the natural process of HIV infection. Some studies have 
revealed that this coinfection aﬀects HIV progression 
and its related mortality (18, 19). Other studies, however, 
have not shown the same results—especially after the 
wide use of HAART (20, 21). In other words, considering 
HAART and controlling its eﬀects, no consensus exists 
regarding the eﬀect of HIV infection on general survival 
or HIV-related survival in HIV patients (22). In addition, 
few studies have been conducted on the survival of HIV 
patients and its factors in Iran. 
2. Objectives
This study aimed to investigate the eﬀect of HCV infec-
tion—after controlling for the eﬀects of HAART—on sur-
vival in a relatively large cohort of HIV patients who have 
a high prevalence of HCV coinfection in Shiraz (South of 
Iran).
3. Patients and Methods
The registration of HIV patients who participated in 
this cohort study began in April 2001. These patients 
were diagnosed as deﬁnite HIV infections (by serial ELISA 
and western blot) among thousands of individuals re-
ferred to this center due to risky behaviors. In the center, 
HIV-infected patients receive free services, such as regu-
lar laboratory and radiological exams, medications pre-
scribed by a physician, and personal and familial consul-
tations. The interviewers were well trained and familiar 
with the patients under study. Also, the quality control of 
the data was done by a researcher. Through July 15, 2011, 
1683 HIV patients took part in this study. The participa-
tion criteria included being visited twice by an infectious 
disease specialist in the past 18 months, determination 
of their survival status in the past 6 months, age over 17 
years, and to be in the cohort study at least for 12 months. 
Accordingly, 1338 patients met the criteria. HAART treat-
ment was performed for some patients in this center in 
2003. Since 2004, however, it has been done routinely for 
eligible patients, based on WHO instructions and their 
adjusted forms, which were prepared and supplied by 
the Iranian Ministry of Health and Medical Education 
(this treatment does not diﬀer between HIV infected 
and HIV/HCV coinfected subjects). The causes of partici-
pants’ deaths were gathered from their proﬁles and con-
ﬁrmed by the general practitioner of the center, who was 
familiar with the patients. In cases for which the status 
of death was not known, the center’s social work depart-
ment called the intended patients or their families and 
conﬁrmed the patient’s survival status. If a patient was 
dead, the exact cause of death was determined and re-
corded through hospital proﬁles or the death certiﬁcate. 
Then, the causes of deﬁnite HIV- and AIDS-related deaths 
were identiﬁed and examined as the event of the study 
(23). A venous sample was taken by a professional phle-
botomist from the arms of all subjects who participated 
in the blood test. By ELIZA, the samples were screened 
for anti-HIV (Delaware Biotech Inc., USA), and the diag-
nosis of HIV was conﬁrmed by western blot (Diagnostic, 
Germany). A third-generation ELISA (Dia. Pro, Italy) was 
used to determine anti-HCV. Positive results from both 
the western blot (for HIV) and third-generation ELISA 
(for HCV) were considered coinfection with HIV and 
HCV. CD4+ cell counts were measured by ﬂow cytometry 
(Partec, Germany). The project was approved by the vice 
chancellor for research aﬀairs, Shiraz University of Medi-
cal Sciences. 
Two periods were deﬁned for the patients: before 
HAART (before 2004) for patients who had been regis-
tered before 2004 and during HAART for patients who 
had been registered after 2004. The patients were cate-
gorized into 2 groups: those who were infected with HCV 
and those who were not. The characteristics of the study 
participants were compared by chi-square test and t-test 
regarding the qualitative and quantitative variables, re-
spectively. The mortality rate from AIDS-related compli-
cations was calculated by dividing the number of deaths 
by time-persons of follow-up in the subgroups; 95% con-
ﬁdence intervals were also calculated. Survival curves of 
the 2 groups were drawn and compared by Kaplan-Meier 
method and log-rank test. Moreover, Cox proportional 
hazards model was used to examine the eﬀect of HCV in-
fection on patient survival, controlling for age, sex, IDU, 
CD4 count at baseline, a greater than 30% decline in CD4 
cell count during the study, and HAART treatment. The 
assumption of analysis in the Cox model was evaluated 
using parallel survival curves. In the survival analyses, 
the time of patient registration and entrance into the 
cohort was considered the starting point (T0), and AIDS-
related death was considered the event of the study. Sta-
tistical analyses were performed using SPSS (version 16) 
and Stata (version 10).
4. Results
In this study, 1338 HIV patients—204 (15.2%) of whom 
were women—were investigated. The median age was 36 
(32–42) years; 1044 (78.03%) of these patients were infect-
ed by HCV. The median follow-up was 43.48 (61.18–26.63) 
months. Other characteristics of the population, based 
on HCV status, are shown in Table 1. Most of the HCV-
infected individuals were males and older and had risk 
factors of more IDU and longer follow-ups in the study. 
The rate of AIDS-related deaths decreased to 74.8% after 
2004 and from 5.59 (95%CI: 3.93–7.96) to 1.41 (95% CI: 1.1–
1.82) deaths per 100 person-years (P < 0.0001). The rate of 
AIDS-related deaths increases 23.23% in people with HIV/
HCV coinfection compared with patients with HIV. The 
mortality rate in patients with HIV/HCV coinfection has 
been 1.98 (95% CI: 1.59 – 2.48) deaths in 100 person-year, 108
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while it has been reported as 1.52 (95% CI: 0.92 – 2.52) 
deaths in 100 person-year in only HIV infected patients. 
(P = 0.03). These rates in HIV/HCV-coinfected persons in 
the pre-HAART and post-HAART periods were 5.51 (95% 
CI: 3.62–8.37) and 1.58 (95% CI: 1.21–2.06) per 100 person-
years, respectively (P < 0.0001). Also, the mortality rate 
was compared between the patients with baseline CD4 
counts below and above 200, which showed an 82.33% in-
crease in patients with baseline CD4 counts below 200. 
The mortality rate of the ﬁrst group (patients with base-
line CD4 counts below 200) was 4.3 (95% CI: 3.25–5.69) per 
100 person-years versus 0.76 (95% CI: 0.47–1.25) per 100 
person-years in the second group (patients with baseline 
CD4 above 200) (P < 0.0001). The median survival time in 
the HCV-infected and uninfected patients was 163.8 and 
194.8 months, respectively (P = 0.039). In the multivariate 
analysis (Table 2), it was revealed that after controlling for 
covariates, HCV infection increased the number of deaths 
in HCV-infected patients 2.13 times (95% CI: 1.1 – 4.52) more 
than HCV-uninfected patients. Covariates of HAART (aHR 
= 0.46; 95% CI: 0.24-0.86), CD4 count at baseline (aHR = 
5.38; 95% CI: 3.04–9.51), and more than a 30% decline in 
CD4 count (aHR = 2.93; 95% CI: 1.65–5.2) correlated with 
survival length in the follow-up (P < 0.05). In order to es-
timate rates of survival by HCV status according to IDU 
and sex, 2 Cox analyses were performed with the (HCV × 
IDU and HCV × sex) interaction terms in the models. The 
lack of statistical signiﬁcance between these interactions 
(P = 0.987 and P = 0.858, respectively) showed that the ef-
fect of HCV on HIV survival was not modiﬁed by IDU or 
gender and did not require a separate analysis. 
5. Discussion
In our large cohort study, the prevalence of HIV/HVC 
coinfection was 78%. This coinfection was related to IDU 
background. Intravenous drug use has been the pre-
dominant mode of transmission of HCV in the world (24, 
25), and approximately 75% HIV-positive people in Iran 
are IDUs (26). The results of the present study are con-
sistent with previous national (27, 28) as well as interna-
tional (29, 30) studies and emphasize IDU as one of the 
major routes of HVC transmission. Our study revealed 
that HAART treatment leads to a 54% decrease in AIDS-re-
lated deaths. Other studies have also shown that HAART 
treatment results in a decrease in mortality rate in HIV 
patients 3 to 10 times more than untreated HIV patients 
with HAART and changes HIV/AIDS into a chronic disease 
(31). The international experience has shown that before 
commencement of HAART treatment, almost all HIV pa-
tients died due to AIDS-related diseases; today, however, 
almost half of these patients in North America and Eu-
rope die from reasons that are not related to AIDS (32). 
HAART treatment not only decreases necrotic inﬂamma-
Patients, (n = 1338) HCV Group, (n = 1044) Non-HCV Group, (n = 294) P value
Females, No. (%) 204 (15.2) 36 (3.4) 168 (57.1) < 0.0001
Age, median (range) 36 (32- 42) 37 (32- 43) 35 (31- 42) 0.002
IDU risk factor, No. (%) 987 (73.8) 918 (87.9) 69 (23.5) < 0.0001
Fallow up time in month, median 
(range)
43.48 (26.23 – 61.58) 45.33 (27.74- 62.5) 37.3 (20.6- 54.8) 0.006
CD4 cell count at base line ≤ 200 cells/
μL, No. (%)
306 (22.9) 224 (21.5) 82 (27.9) 0.78
> 30% decline in CD4 cell count at fallow 
up time, No. (%)
145 (10.8) 106 (10.2) 39 (13.3) 0.89
HAART therapy, No. (%) 0.75
No (before 2005) 134 (10) 106 (10.2) 28 (9.5)
Yes (after 2005) 1204 (90) 938 (89.8) 266 (90.5)
Table 1. Demographic and Baseline Characteristics of the Study Cohort Divided Into the Groups Infected With Hepatitis C Virus and Not Infected With 
Hepatitis Virus C
Value or Characteristic Compared Crude Hazards Ratio Adjusted Hazards Ratio P value
Age 1 year increasing 0.997 (0.975-1.02) 0.99 (0.96- 1.02) 0.647
Sex Female vs. male 0.57 (0.28- 1.17) 0.54 (0.2- 1.44) 0.216
IDU Non IDU vs. IDU 0.996 (0.63- 1.57) 0.84 (0.46- 1.54) 0.57
CD4 cell count at base line < 200 vs. ≥ 200 cells/μL 4.3 (2.5- 7.2) 5.38 (3.04- 9.51) < 0.0001
Decline in CD4 cell count 
during fallow up
Yes vs. No 1.64 (0.95- 2.8) 2.93 (1.65- 5.2) < 0.0001
HCV Positive vs. Negative 1.9 (1.1- 3.5) 2.13 (1.1- 4.52) 0.048
HAART Yes vs. No 0.36 (0.21- 0.59) 0.46 (0.24- 0.86) 0.015
Table 2. Multivariate Analysis of the Time to HIV/AIDS Related Death109
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tion and progressive liver diseases (33, 34) but also reduc-
es the replication of viruses in the liver (34) and increases 
the CD4 count (35). On the other hand, HAART treatment 
is advised to be performed before beginning HCV treat-
ment, since it may cause ﬁbrosis through cumulative 
hepatotoxicity in HIV/HCV-coinfected patients.
Regardless, the results of the present study were con-
sistent with the results of other studies, and emphasize 
the important role of HAART treatment in the survival 
of HIV patients (36). As expected, CD4 count at baseline 
correlated with AIDS-related death. CD4 T cells are the 
primary target of HIV and an important marker in evalu-
ating the immune system’s health. Decline of CD4 cells 
through increased infections by opportunistic diseases 
results in an rise in HIV-related deaths (32). In addition 
to CD4 count at baseline and last CD4 count before 
HAART treatment, the duration of a patient’s life with a 
high CD4 count inﬂuences his prognosis; a 30% decline 
in CD4 count during the follow-up shows that patients 
are more at risk and consequently aﬀects their survival 
(31, 37). These results are consistent with the results of 
other researchers and emphasize the importance of the 
follow-up of patients’ CD4 count during HAART (38). The 
results of the present study show that HCV infection in 
HIV-infected patients increases AIDS-related deaths by 
2.13 times, consistent with most of the results of other 
studies (18, 39, 40). On the other hand, many studies have 
not found a relationship between this coinfection and 
overall death rates before HAART treatment or between 
this coinfection and AIDS-related deaths after HAART 
treatment, as shown in a meta-analysis of 30 studies and 
over 100,000 patients (22). These variations might be due 
to the type of HAART treatment, adherence of patients to 
HAART treatment, diﬀerent endpoints, various sample 
sizes, diﬀerent follow-up times, and ignoring some alter-
ing factors. Fortunately, the type of treatment and the 
deﬁnition of AIDS-related death are clear in our popula-
tion; ie, per the Shiraz Center of Behavioral Consult. The 
sample size and the follow-up time are also suitable. Al-
though no independent studies have been conducted on 
the status of patient adherence in this center, primary 
surveys as well as the experiences of doctors report the 
25% to 30% treatment failure, which is in line with other 
national studies (41). The treatment failure might be af-
fected by the high proportion of IDU and, consequent-
ly, the high proportion of HIV/HCV coinfection, which 
strongly aﬀects patient adherence to HAART treatment. 
In spite of the fact that the mechanisms through which 
HCV infection worsens the condition of HIV patients and 
increases its complications and AIDS-related deaths are 
not clear, it likely activates immune cells with the CD4 
apoptosis marker and causes a severe defect in the im-
mune system (42), decreasing the power of recovery in 
CD4 T cells after HAART treatment (43); increasing the 
production of cryoglobulin by activation of B cells (44), 
decreasing the production of CRP (45); and activating 
the replication of HCV in lymphoid (46) and lymphoblas-
tic (47) tissues as well as in environmental CD4 T cells in 
HIV patients (48). The present study revealed that HAART 
treatment is highly eﬀective in HIV patients in Iran. In 
addition, HCV coinfection, as an independent factor, can 
threaten these patients. These ﬁndings should prompt 
us to prevent HCV infection and eliminate this virus in 
HIV patients. Conducting programs for screening blood 
of HCV and HCV RNA antibodies is quite beneﬁcial. Fortu-
nately, this program is being seriously conducted in Iran 
and, particularly, Fars (49), as well as some developed 
and developing countries. Harm reduction programs in 
at-risk populations – particularly HIV patients – is also of 
great importance. Fortunately, these programs are also 
being conducted in a high quantity and quality in Iran; 
in 2007, the Iranian health system distributed 1,400,000 
syringes in DIC and outreach teams that provide harm 
reduction services over 6 months (50). Therefore, this 
coinfection should decrease. Nevertheless, based on 
other countries’ previous experiences, harm reduction 
programs for HCV transmission in IDU people are less ef-
fective than for those with HIV. This is probably due the 
higher transmission of HCV and the larger number of 
HCV-infected patients in the IDU population (12). Timely 
diagnosis of HCV infection is also of great signiﬁcance 
(12). In the next stage, the eﬀective treatment of these 
patients, as secondary prevention, is quite inﬂuential; 
however, it was not widely performed in the population 
under our investigation.
Surveys show that less than 10% of the 170 million HCV-
infected patients around the world are aware of their 
disease. As man is the only reservoir of HCV, elimination 
of the virus is not that far-fetched. Moreover, in contrast 
to HBV and HIV, there is no latent reservoir for this virus; 
and when a patient is cured, the danger of transmission 
of the virus to others is eliminated. If the environmental 
reservoir is suﬃciently decreased, the infection cannot 
be transmitted easily, allowing the virus transmission 
cycle to be broken easily using proper disinfectants (12). 
The present study had some limitations. Since HCV RNA 
could not be detected routinely in the population under 
study, HCV infection could only be diagnosed by serol-
ogy, based on HCV Ab. Of course, this could not strongly 
aﬀect the results of our study, since at least 1 year had 
passed from the participants’ HIV infection and their 
entrance into the cohort. Further, the sensitivity of HCV 
Ab is over 99% (51). On the other hand, as others have 
mentioned, serological study of HCV infections might 
underestimate the eﬀect of HCV on AIDS-related com-
plications. Therefore, had we measured HCV RNA, we 
would have observed a stronger relationship between 
HCV infection and AIDS-related deaths (51). The second 
limitation was that the role of some infections, such as 
GB virus C and transfusion transmitted virus (TT Virus), 
was not investigated with regard to the relationship be-
tween HCV infection and AIDS-related deaths, since they 
were not routinely measure in our study population. As 
others have also shown, GB virus C leads to a decrease in 
HIV replication and improvements in HIV patients’ sur-
vival. On the other hand, it can be sexually transmitted, 110
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and its prevalence is the same in infected people, IDU 
people, and other groups. Therefore, this virus cannot 
have altered the relationship between HCV infection and 
AIDS-related deaths (19).
Third, we did not know the exact time of HIV and HCV 
infection; thus, we considered the time of the laboratory 
exam as the time of infection. However, this moot point 
can change the actual impact of HCV on HIV/AIDS-related 
endpoints. Although our study revealed that HCV infec-
tion was diagnosed after HIV infection and entrance of 
the subjects into the study in nearly 90% of subjects, the 
exact time of HCV infection is not known. Fourth, be-
cause subjects entered our study at diﬀerent stages of 
HIV/AIDS, it was very diﬃcult to control for disease state 
on survival estimations. Fortunately, our evaluation re-
vealed that because the center is unique in Shiraz, nearly 
all of our subjects were in the initial stages of infection. 
Besides, the impact of disease progression on survival 
was controlled by the baseline and trend of CD4 counts. 
The study sample was selected from a large population of 
HIV patients who solely and inevitably demand the coun-
try’s health and treatment centers to treat their disease. 
These patients are from diﬀerent cultural, social, and 
economic backgrounds. Further, because this center is 
the only provider of such services in Fars and some parts 
of southern Iran, this sample is a proper representative 
of the population of HIV patients in southern Iran. More-
over, regarding the results of other studies and consid-
ering the similarities between our study population and 
other parts of Iran, this sample can also be a proper rep-
resentative of the entire country (52). HAART treatment 
in the Iranian study population obviously improved 
HIV patients’ survival. After controlling for the eﬀect of 
HAART treatment, HCV infection resulted in an increase 
in AIDS-related deaths. In addition, our study enjoys a 
major practical application: it emphasizes the neces-
sity of timely diagnosis and treatment, as well as serious 
harm reduction programs, in order to control and elimi-
nate HCV infection and transmission.
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